Compare Novartis AG (NVS) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Global X Robo Global Robotics & Automation ETF — how do they compare? Novartis AG trades at $143.11 (market cap $268.57B), while Global X Robo Global Robotics & Automation ETF trades at $81.2 (market cap $2.06B). The key difference: Novartis AG is far larger — about 130.4× Global X Robo Global Robotics & Automation ETF's market cap, and Novartis AG pays a 3.31% dividend while Global X Robo Global Robotics & Automation ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Global X Robo Global Robotics & Automation ETF for 36 Days on average.
| NVS | ROBO | |
|---|---|---|
Market Cap | $268.57B | $2.06B |
Volume | 1,532,573 | 148,111 |
Sector | Health | Sector/Thematic |
52-Week High | $168.62 | $90.34 |
52-Week Low | $121.80 | $63.04 |
Typical Hold Time | 82 Days | 36 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
ROBO trades at $81.82, down 1.89% today amid mixed technical signals. The overall technical outlook remains bullish with strong moving average support, though oscillators show bearish momentum with RSI levels above 79 indicating potential overbought conditions. Recent news highlights accelerating robotics adoption across manufacturing, healthcare, and military applications, with Q2 2026 earnings showing broadening demand for physical AI technologies.
The robotics ETF offers diversified exposure to a sector benefiting from labor shortages and AI infrastructure growth. Key risks include valuation concerns amid rapid sector expansion and potential market volatility. Analyst coverage remains positive on long-term robotics adoption trends, though current technical indicators suggest near-term consolidation may be needed after recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
